Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis

Fernando M. Runzer-Colmenares
, Rossana Ruiz
, Lorenzo Maco
, Mike Maldonado
, Luis Puma-Villanueva
, Marco Galvez-Nino
, Carlos Aliaga
, Vicente A. Benites-Zapata
, Carlos Diaz-Arocutipa
, Luis Mas
, Diego Urrunaga-Pastor^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science